AstraZeneca PLC (AZNCF)
| Market Cap | 240.71B |
| Revenue (ttm) | 56.50B |
| Net Income (ttm) | 8.30B |
| Shares Out | n/a |
| EPS (ttm) | 5.31 |
| PE Ratio | 29.02 |
| Forward PE | 15.90 |
| Dividend | 3.13 (1.96%) |
| Ex-Dividend Date | Aug 7, 2025 |
| Volume | 100 |
| Average Volume | 4,257 |
| Open | 157.73 |
| Previous Close | 154.58 |
| Day's Range | 153.00 - 157.73 |
| 52-Week Range | 120.64 - 164.82 |
| Beta | 0.17 |
| RSI | 44.97 |
| Earnings Date | Nov 6, 2025 |
About AstraZeneca
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Crestor, Seloken, Lokelma, Roxadustat, Andexxa, Wainua, Symbicort, Fasenra, Pulmicort, Breztri/Trixeo, Saphnelo, Tezspire, Airsupra, Ultomiris, Soliris, Strensiq, Koselugo, Kanuma, Atacand, Plendil, Modip, Splendil, Munobal, Flodil, Komboglyze, Qtern, B... [Read more]
Financial Performance
In 2024, AstraZeneca's revenue was $54.07 billion, an increase of 18.03% compared to the previous year's $45.81 billion. Earnings were $7.04 billion, an increase of 18.14%.
Financial StatementsNews
AstraZeneca Puts Cambridge Expansion On Ice Adding Pressure On Starmer Ahead Of Trump Visit
The U.K.-based AstraZeneca Plc (NASDAQ: AZN) paused a planned 200 million pounds ($271.26 million) investment in its Cambridge research site. AstraZeneca spokesperson told Reuters the company regular...
AstraZeneca Puts Cambridge Expansion On Ice Adding Pressure On Starmer Ahead Of Trump Visit
The U.K.-based AstraZeneca Plc AZN paused a planned 200 million pounds ($271.26 million) investment in its Cambridge research site.
AstraZeneca shares down 3% after rating cut, UK investment pause
AstraZeneca shares fell as much as 3.4% on Monday, their steepest drop since May, after Handelsbanken cut its rating on the drugmaker and Reuters reported the company had paused a major investment in ...
AstraZeneca Pauses Plans for $271 Million Expansion of U.K. Site
How the UK fell out with big pharma
The U.K. is in the midst of a falling out with big pharma over drug pricing. Merck has walked away from a 1 billion facility in London and pulled its research activities altogether. Now Eli Lilly, San...
AstraZeneca (AZN) Halts $271M UK Investment Amid Economic Uncertainty
AstraZeneca (AZN) Halts $271M UK Investment Amid Economic Uncertainty
AstraZeneca's £200m blow to Labour as pharma giant scraps major investment
Hours after official figures showed output from the pharmaceuticals industry in the UK fell 4.5 per cent in July, Britain's biggest firm said the project at its research site has been 'paused'.
AstraZeneca pauses £200m expansion in Cambridge
It comes after the pharmaceutical firm abandoned plans to invest £450 million in a vaccine plant in Merseyside earlier this year.
AstraZeneca pauses £200m Cambridge investment
Its decision comes as the industry says there is a lack of government investment and as the US pressures firms to invest there.
AstraZeneca (AZN) Halts $271M Investment in UK Amid Uncertainty
AstraZeneca (AZN) Halts $271M Investment in UK Amid Uncertainty
AstraZeneca (AZN) Halts Major Investment in UK Research Facility
AstraZeneca (AZN) Halts Major Investment in UK Research Facility
AstraZeneca pauses £200mn Cambridge investment amid UK pharma uncertainty
AstraZeneca has become the latest major drugmaker to scale back investment in the United Kingdom, pausing a planned £200 million ($271 million) expansion of its Cambridge research site. The move, whic...
AstraZeneca follows Merck’s pullback in Britain: report
AstraZeneca pauses £200m investment in Cambridge research site
Decision means none of drugmaker’s much-trumpeted £650m UK investment package is currently proceeding The drugmaker AstraZeneca has paused a planned £200m investment in its Cambridge research site, co...
Exclusive: AstraZeneca pauses $270 million investment in Britain
Britain's biggest company AstraZeneca has paused a planned 200 million pound ($271.26 million) investment in its Cambridge research site, a spokesperson said, the latest drugmaker to retreat from Brit...
AstraZeneca (AZN) Advances Enhertu EMA Application for Broad Tumor Treatment
AstraZeneca (AZN) Advances Enhertu EMA Application for Broad Tumor Treatment
US tariffs, pricing risks to be manageable for Big Pharma, Morningstar says
The impact of U.S. President Donald Trump's plan to levy import duties on pharmaceutical products and his push to lower drug prices are likely to be manageable for big U.S. and European drugmakers, ac...
AZN: New Regulations Aim to Enhance Drug Advertising Transparency
AZN: New Regulations Aim to Enhance Drug Advertising Transparency
Trump's Biotech Playbook Ignites $350 Billion Investment Blitz
Biotech is back – and it's playing for keeps. President Donald Trump 's second-term policies have unleashed a staggering ~$350 billion surge in U.S.-based pharmaceutical and biotech investments , from...
AstraZeneca Lung Cancer Combo Extends Patient Survival By Years In Key Study
On Sunday, AstraZeneca Plc (AZN) released results from the final overall survival (OS) analysis of the FLAURA2 Phase 3 trial in previously untreated patients with locally advanced (Stage IIIB-IIIC) or...
AstraZeneca (AZN) Study Shows Enhanced Survival with TAGRISSO and Chemotherapy
AstraZeneca (AZN) Study Shows Enhanced Survival with TAGRISSO and Chemotherapy
TN signs MoUs with Hinduja, AstraZeneca
Chennai: State govt represented by chief minister M K Stalin signed a memorandum of understanding (MoU) worth 7,500 crore with UK-based Hinduja Group .
Sanofi Hit With Shock As Flagship Drug Successor Disappoints Investors
French drugmaker Sanofi SA (NASDAQ: SNY) stock fell sharply Thursday after late-stage trial results for amlitelimab, its potential successor to blockbuster eczema drug Dupixent, failed to match inves...
AstraZeneca, Corning And More On CNBC's 'Final Trades'
On CNBC's “ Halftime Report Final Trades ,” Jim Lebenthal , partner at Cerity Partners, named AstraZeneca PLC (NASDAQ: AZN) as his final trade . On Aug. 20, AstraZeneca released complete results from...
Global drugmakers rush to boost US presence as tariff threat looms
Global drugmakers are scrambling to shore up their U.S. manufacturing capacity and domestic inventory as the Trump administration weighs hefty tariffs on pharmaceutical imports into the country.